Piyasa açık· · DKK · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
Investment increases production capacity, supports booming consumer demand and reinforces Wisconsin's leadership in dairy biosolutions West Allis Ribbon Cutting Anders Lund, Chief Operating Officer and Executive Vice President at Novonesis cuts the ribbon at the West Allis ceremony. West Allis Ribbon Cutting Group photo at the Novonesis West Allis ribbon cutting on Friday, September 25 WEST ALLIS, Wis., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Novonesis, a global leader in biosolutions, announced the
Expansion in Patalganga puts Novozymes under the spotlight Novozymes (CPSE:NSIS B) has come into focus after Novonesis announced a €600 million plan to expand its Patalganga site, with the aim of increasing biosolutions capacity for customers across high growth markets. For context, Novozymes shares last closed at DKK429.4. A 90-day share price return of 13.00% points to building momentum, even though the 1-year total shareholder return of 8.50% and the 5-year total shareholder return, which...
Today, Novonesis will initiate the first tranche (the “First Tranche”) of the EUR 1 billion multi-year share buyback program announced in Company Announcement No. 14, on August 19, 2026. Under the First Tranche, Novonesis will acquire B shares for an aggregate amount of up to EUR 75 million, with the First Tranche expected to end no later than December 17, 2026. Based on the closing share price on September 11, 2026, the First Tranche corresponds to around 1.3 million B shares. The shares acquir
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.